Why 10x Genomics Stock Was Sliding This Week
Gene sequencing technology company 10x Genomics (NASDAQ: TXG) hasn't been having it easy in the past few days on the stock market. A bearish analyst move dampened sentiment on the company, and according to data compiled by S&P Global Market Intelligence its price was down by more than 9% week to date as of early Friday morning.
That occurred on Monday, when Tejas Savant from white-shoe investment bank Morgan Stanley reduced his 10x Genomics price target to $18 per share, far down from his previous level of $26. Despite that, Savant maintained his overweight (buy, in other words) recommendation on the shares.
Image source: Getty Images.
Source Fool.com
